Cargando…

How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts

OBJECTIVES: The International Respiratory Coalition’s Lung Facts web resource provides the latest data on a range of lung conditions covering the World Health Organization’s European Region, informed by the Global Burden of Disease studies: https://international-respiratory-coalition.org/lung-facts/...

Descripción completa

Detalles Bibliográficos
Autores principales: Franklin, Matthew, Angus, Colin, Welte, Tobias, Joos, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232602/
https://www.ncbi.nlm.nih.gov/pubmed/37039953
http://dx.doi.org/10.1007/s40258-023-00802-y
_version_ 1785052018797182976
author Franklin, Matthew
Angus, Colin
Welte, Tobias
Joos, Guy
author_facet Franklin, Matthew
Angus, Colin
Welte, Tobias
Joos, Guy
author_sort Franklin, Matthew
collection PubMed
description OBJECTIVES: The International Respiratory Coalition’s Lung Facts web resource provides the latest data on a range of lung conditions covering the World Health Organization’s European Region, informed by the Global Burden of Disease studies: https://international-respiratory-coalition.org/lung-facts/. Within Lung Facts, disability-adjusted life-years (DALYs) are monetised based on gross domestic product (GDP) per capita. We describe the conceptual and empirical basis for using monetised DALYs to inform negotiations with policymakers to invest in lung care across the World Health Organization European region. METHODS: We reflect on the existing debate and research evidence regarding the X value in an X*GDP per capita framework to monetise DALYs, with a focus on if 1*GDP per capita is conceptually and practically appropriate. Using an asthma case study, Global Burden of Disease study 2019 DALY estimates per country are presented. Gross domestic product per capita are converted to international dollars using purchasing power parity (Int$2019). RESULTS: Using 1*GDP per capita, the estimated monetised asthma DALY burden, for example, in Kyrgyzstan or Germany is: across the whole population, $44,860,483 or $9,264,767,882, respectively; per 100,000 people, $731,600 or $10,208,317, respectively. CONCLUSIONS: Our indicative monetised DALY estimates can enable informed discussions with policy and decision makers, to guide financial investment in alleviating the burden of lung conditions. We suggest 1*GDP per capita as a benchmarked value forms a starting point for negotiation with policymakers for investing in lung care, by scaling the estimated lung condition DALY burden to the resource available in each country to tackle the burden. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-023-00802-y.
format Online
Article
Text
id pubmed-10232602
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-102326022023-06-02 How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts Franklin, Matthew Angus, Colin Welte, Tobias Joos, Guy Appl Health Econ Health Policy Practical Application OBJECTIVES: The International Respiratory Coalition’s Lung Facts web resource provides the latest data on a range of lung conditions covering the World Health Organization’s European Region, informed by the Global Burden of Disease studies: https://international-respiratory-coalition.org/lung-facts/. Within Lung Facts, disability-adjusted life-years (DALYs) are monetised based on gross domestic product (GDP) per capita. We describe the conceptual and empirical basis for using monetised DALYs to inform negotiations with policymakers to invest in lung care across the World Health Organization European region. METHODS: We reflect on the existing debate and research evidence regarding the X value in an X*GDP per capita framework to monetise DALYs, with a focus on if 1*GDP per capita is conceptually and practically appropriate. Using an asthma case study, Global Burden of Disease study 2019 DALY estimates per country are presented. Gross domestic product per capita are converted to international dollars using purchasing power parity (Int$2019). RESULTS: Using 1*GDP per capita, the estimated monetised asthma DALY burden, for example, in Kyrgyzstan or Germany is: across the whole population, $44,860,483 or $9,264,767,882, respectively; per 100,000 people, $731,600 or $10,208,317, respectively. CONCLUSIONS: Our indicative monetised DALY estimates can enable informed discussions with policy and decision makers, to guide financial investment in alleviating the burden of lung conditions. We suggest 1*GDP per capita as a benchmarked value forms a starting point for negotiation with policymakers for investing in lung care, by scaling the estimated lung condition DALY burden to the resource available in each country to tackle the burden. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-023-00802-y. Springer International Publishing 2023-04-11 2023 /pmc/articles/PMC10232602/ /pubmed/37039953 http://dx.doi.org/10.1007/s40258-023-00802-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Practical Application
Franklin, Matthew
Angus, Colin
Welte, Tobias
Joos, Guy
How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts
title How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts
title_full How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts
title_fullStr How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts
title_full_unstemmed How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts
title_short How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts
title_sort how much should be invested in lung care across the who european region? applying a monetary value to disability-adjusted life-years within the international respiratory coalition’s lung facts
topic Practical Application
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232602/
https://www.ncbi.nlm.nih.gov/pubmed/37039953
http://dx.doi.org/10.1007/s40258-023-00802-y
work_keys_str_mv AT franklinmatthew howmuchshouldbeinvestedinlungcareacrossthewhoeuropeanregionapplyingamonetaryvaluetodisabilityadjustedlifeyearswithintheinternationalrespiratorycoalitionslungfacts
AT anguscolin howmuchshouldbeinvestedinlungcareacrossthewhoeuropeanregionapplyingamonetaryvaluetodisabilityadjustedlifeyearswithintheinternationalrespiratorycoalitionslungfacts
AT weltetobias howmuchshouldbeinvestedinlungcareacrossthewhoeuropeanregionapplyingamonetaryvaluetodisabilityadjustedlifeyearswithintheinternationalrespiratorycoalitionslungfacts
AT joosguy howmuchshouldbeinvestedinlungcareacrossthewhoeuropeanregionapplyingamonetaryvaluetodisabilityadjustedlifeyearswithintheinternationalrespiratorycoalitionslungfacts